SYMATESE expands into Australia, Canada and New Zealand

We are pleased to announce that Symatese Expands Strategic Partnership with Evolus to enter those key market to to Commercialize ESTYME®. See press release.

This agreement is part of Symatese’s Transform Plan 2025-2029 and our continued international growth strategy, and will allow more physicians and healthcare professionals to access this unique portfolio of HA injectables based on our breakthrough COLD-X TECHNOLOGY by SYMATESE, ultimately improving patient outcomes.